Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 12OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 3Recurrence 2Multiple Myeloma 2Lymphoma, Follicular 2Immunoblastic Lymphadenopathy 2Esophageal Squamous Cell Carcinoma 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 30N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 21Prednisone 20Etoposide 20Vincristine 16Whole-Body Irradiation 15Doxorubicin 15fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 14romidepsin 13Mycophenolic Acid 12Lenalidomide 12Gemcitabine 12Cyclosporine 10Azacitidine 10Brentuximab Vedotin 9Bortezomib 9Alemtuzumab 8Dexamethasone 7Methotrexate 6Cytarabine 6Busulfan 6Carmustine 5pembrolizumab 4fludarabine 4Vorinostat 4Tacrolimus 4Rituximab 4Melphalan 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Peripheral × 10-propargyl-10-deazaaminopterin × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT01947140 2022-11-23

PDX+Romi

Columbia University

Phase 1/2 Completed
57 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Columbia University

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03356678 2017-11-29

Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma

Samsung Medical Center

Completed
33 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡